| Drug Name: | Cetuximab (205923-56-4) |
|---|---|
| PubChem ID: | 124080266 |
| SMILES: | CCC(=O)O[C@@H]1[C@H](CC(=O)C2=C(C3=C(C=CC(=C3O)C4=C(C5=C(C=C4)O[C@]6([C@@H]([C@H](CC(=O)C6=C5O)C)OC(=O)CC)C(=O)OCC)O)O[C@@]12C(=O)OCC)O)C |
| InchiKey: | UHNVIUHENOTFPJ-ASARQVCMSA-N |
| Therapeutic Category: | Antineoplastic Agents |
| Molecular Weight (dalton) | : | 778.76 |
| LogP | : | 4.553 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 16 |
| Hydrogen Bond Donor Count | : | 4 |
| Total Polar Surface Area | : | 238.72 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Tumors Express | Epidermal growth factor receptor precursor (P00533) | Cetuximab on this once-weekly schedule has modest activity and is well-tolerated as a single agent in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor. [ ADR Type 2 ] | Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category